EX-10.410-Q·CIK 1788028·0001213900-26-120161

Third Amendment to License Agreement, Dated July 9, 2026, by and Between the Trustees of the University of Pennsylvania and Kira Pharmaceuticals

View original filing on SEC EDGAR → ·  seen Nov 16, 2026, 08:06 EST

Exhibit 10.4

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

**UNIVERSITY of PENNSYLVANIA

Third Amendment to License Agreement

This Third Amendment to the License Agreement effective as of July 9, 2026 (this *Third Amendment *, is made by and between The Trustees of the University of Pennsylvania *Penn *and Kira Pharmaceuticals ( *Licensee *) and amends the License Agreement between the Parties, dated June 9, 2017, as amended by the First Amendment to the License Agreement effective as of June 7, 2019 and the Second Amendment to License Agreement effective as of February 4, 2021 (collectively, the *License Agreement *; Penn reference [***]).

BACKGROUND

WHEREAS, the License Agreement relates to certain intellectual property developed by Dr. Wenchao Song of Penn’s Perelman School of Medicine, which intellectual property is the subject of patents or patent applications and is related to antibody therapeutics against complement proteins C5, factor D and C5a;

WHEREAS, Penn developed certain new technologies relating to treatment of complement mediated diseases (Penn docket references:[***], [***], [***], [***]) through a sponsored research agreement between Penn and Licensee, dated January 1, 2021 (Penn reference [***]) and Licensee desires to obtain a license to Penn’s rights in certain intellectual property rights to such new technologies;

WHEREAS, Licensee is developing various products based on the Penn Patent Rights;

WHEREAS, Licensee has had difficulty in the past few years raising adequate funding for the continued development and commercialization of the Products, and now has the opportunity to go public through a reverse merger transaction (the *Reverse Merger Transaction *contemporaneous with a Private Investment in Public Equity transaction *PIPE Transaction *providing capital to the Licensee to continue the development and commercialization of products based on the Penn Patent Rights;

WHEREAS, investors leading a near term convertible bridge round *Bridge Round *and the PIPE are requesting updates and modifications to the License Agreement as provided herein as part of their investment in the Bridge Round and PIPE;

WHEREAS, Licensee will have the ability to pay and shall pay all outstanding amounts owed to Penn upon the execution of this Third Amendment; and WHEREAS, it is in the interest of the Parties to facilitate the Bridge Round, the Reverse Merger Transaction and the associated PIPE and to effectuate such an amendment to the License Agreement as requested by the associated investors as provided under the terms and conditions of this Third Amendment.

NOW, THEREFORE, the Parties hereby agree as follows:

1) Within [***] of the effective date of this Third Amendment, Licensee shall pay Penn a license amendment fee of [***] (the License Amendment Fee”).
2) As of May 30, 2026, Licensee has a balance of: (i) [***] for outstanding patent costs to Penn; (ii) [***] for outstanding Milestone Payment for achieving a Milestone event of [***]; and (iii) [***] for outstanding License Maintenance Fees incurred in calendar years 2025 and 2026 (collectively, the *Outstanding Patent Costs and Fees *Licensee hereby agrees to pay the entire balance of the Outstanding Patent Costs and Fees to Penn within [***] of the effective date of this Third Amendment.
3) Section 9.6 (Successors and Assignment) of the License Agreement is hereby amended to include new Section 9.6.4 as follows:

“9.6.4 Notwithstanding the foregoing, in no event shall Licensee be permitted to assign this Agreement to an entity that is incorporated or located within any country under comprehensive sanctions by the United States government, or that has an Affiliate incorporated or located within any country under comprehensive sanctions by the United States government.”

4) Section 1.3 of the License Agreement is amended and restated in its entirety as follows:

1.3 Change of Control means the occurrence of any of the following events (including through a transaction or series of transactions): (i) any party becomes the owner, directly or indirectly, of more than fifty percent (50%) of the total voting power (on an as converted basis) of the equity units or other interests of Licensee then outstanding that are normally entitled to vote in the election of directors of Licensee; (ii) the merger, consolidation, or amalgamation of Licensee with or into any other party, other than any transaction in which the holders of the outstanding voting securities of Licensee immediately prior to the transaction own, directly or indirectly, not less than fifty percent (50%) of the total voting power (on an as converted basis) of the voting securities of the party surviving such merger, consolidation or amalgamation; (iii) the sale, transfer or other disposition of all or substantially all of the assets of Licensee (iv) the sale transfer or other disposition of this Agreement; (v) an initial public offering of the stock or securities of Licensee in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, or the securities laws of any other jurisdiction resulting in at least [***] in gross proceeds to the Licensee and where the closing of the sale of shares Licensee to the public is at a price of at least three times [***] the price of the per share price sold in the first private securities financing of the Licensee in which an institutional investor participates in *IPO *; or (vi) the consummation of any transaction or series of related transactions pursuant to which Licensee becomes a publicly traded company, including without limitation any reverse merger, reverse takeover, business combination with a special purpose acquisition company (SPAC), or similar transaction, whether or not the holders of the outstanding voting securities of Licensee immediately prior to such transaction retain a majority of the voting power of the surviving or resulting entity.

2
5) Section 1.5 of the License Agreement is hereby amended and restated in its entirety as follows:

“1.5 Commercially Reasonable Efforts means the efforts and resources that [***]. Without limiting the foregoing, Commercially Reasonable Efforts requires, with respect to such obligations, that the Party (a) promptly assign responsibility for such obligation to specific employee(s) who are accountable for progress and monitor such progress on an ongoing basis, (b) set annual objectives for carrying out such obligations, and (c) allocate resources designed to advance progress with respect to such objectives.

6) The Change of Control Fee in the CERTAIN FINANCIAL TERMS section in Exhibit B of the License Agreement is hereby amended and replaced in its entirety with the following:

“Change of Control Fee. In the event the Licensee undergoes a Change of Control, Licensee will pay to Penn a one-time Change of Control Fee as defined below. The

“Change of Control Fee” shall mean the higher of (a) [***] of the Transaction Value of the Licensee at the time of Change of Control, provided that such Change of Control Fee will not exceed [***] and (b) [***].”

7) For further clarity, the *Reverse Merger Transaction *as referenced in the Background Section of this Third Amendment shall be considered as a Change of Control under the License Agreement and shall trigger a “Change of Control Fee” payable to . For clarity, upon the payment of the Change of Control Fee whether pursuant to the Reverse Merger Transaction or otherwise, there will be no future Change of Control Fee due under the License Agreement.
8) Section 1.19 of the License Agreement is deleted and replaced with the following:

“1.19 “Patent Family” means the Penn Patent Rights listed in Exhibit A that are associated with discrete patent families, namely, the “fD Patent Family” which means Penn Patent Rights with the Penn reference [***], [***] and 23- the “C5 Patent Family” which means Penn Patent Rights with the Penn reference [***], [***], [***], [***] and [***] the “C5a Patent Family” which means Penn Patent Rights with the Penn reference [***] and [***] and the “C2 Patent Family” which means Penn Patent Rights with the Penn reference [***] (each of fD Patent Family, C5 Patent Family, C5a Patent Family and C2 Patent Family, a “Patent Family” and collectively, the “Patent Families”).”

9) Exhibit A to the License Agreement is hereby amended and restated in its entirety and is replaced by Appendix 1 to this Third Amendment.
3
10) Section 8.3.2 of the License Agreement is hereby amended and restated in its entirety as follows:

8.3.2 In the event that Licensee fails to achieve any Diligence Event for a second Patent Family, a third Patent Family or fourth Patent Family by its respective Achievement Date and no extension is granted by Penn, Penn may terminate the License for either the second, third, or fourth Patent Family upon written notice as provided in the following sentence. Within [***] of such written notice from Penn, Licensee shall provide Penn of Licensee’s selection of which Patent Family to terminate (either the second, third or fourth) under this Section 8.3.2 and upon Licensee’s election, the License for such selected Patent Family shall be terminated. For clarity, the selection of which Patent Family shall be the terminated Patent Family under this Section 8.3.2 shall be at Licensee’s sole discretion.

11) The notice addresses for the Parties in Section 9.11 (Notices and Deliveries) of the License Agreement are hereby deleted and replaced with the following:

* *

For Penn ** ** **_*with a copy to:*_**
Penn Center for Innovation University of Pennsylvania
University of Pennsylvania Office of General Counsel
3600 Civic Center Blvd., 2929 Walnut Street, Suite 400
9th Floor Philadelphia Philadelphia, PA 19104-5509
PA 19104-4310 Attention: General Counsel
Attention: Managing Director

* *

**_*For Licensee:*_**

** **

Kira Pharmaceuticals

245 Main Street, 12th Floor

Cambridge, MA 02142

Attention: President

12) Upon the payment of the Outstanding Patent Costs and Fees pursuant to Section 2 of this Third Amendment, the License Agreement is amended as follows:
a. The Diligence Event and Achievement Date table in the DEVELOPMENT & COMMERCIALIZATION section of Exhibit B in the License Agreement is amended and replaced with the following table:
Diligence Event Achievement Date
[***] [***]
[***] [***]
[***] [***]
4
b. Section 3.3.1 of the License Agreement is amended and restated in its entirety as follows:

“3.3.1 Licensee and its Sublicensees shall achieve each Diligence Event by the corresponding Achievement Date for a first Product covered by the C5 Patent Family. Licensee and its Sublicensees shall achieve each Diligence Event for a first Product covered by a second Patent Family within [***] of the corresponding Achievement Date for a first Product covered by the C5 Patent Family. Licensee and its Sublicensees shall achieve each Diligence Event for a Product covered by a third Patent Family within [***] of the Achievement Date of a first Product covered by the C5 Patent Family. License and its Sublicensees shall achieve each Diligence Event for a Product covered by the last and fourth Patent Family within [***] of the Achievement Date of a first Product covered by the C5 Patent Family. Licensee and its Sublicensees may extend any Achievement Date for a Diligence Event by [***] (which shall adjust subsequent Achievement Dates), but not more than [***] per Diligence Event by making a payment of [***] to Penn prior to the expiration of such Achievement Date for such Diligence Event. After the exhaustion of the extension right as provided in the sentence above, in the event prior to the expiration of an Achievement Date, Licensee presents to Penn a reasonable explanation on why it will not be able to achieve such Diligence Event prior to the Achievement Date and that Licensee has, and currently is, using Commercially Reasonable Efforts toward the completion of such Diligence Event, Penn will not unreasonably withhold, condition or delay a request for extension(s) to achieve such Diligence Event, subject to a fee to be negotiated by the Parties that in no event shall exceed [***].”

c. The Royalty table in the CERTAIN FINANCIAL TERMS section of Exhibit B of the License Agreement is amended and replaced in its entirety with the following table:
Royalty Rate (% of Net Sales) For Portion of Annual Net Sales
[***] [***]
[***] [***]
[***] [***]
d. The Penn Sublicense Income table in Exhibit B of the License Agreement is amended and replaced in its entirety with the following table:
Sublicense Fee Percentage ** ** Sublicense Fee Milestones
[***] [***]
[***] [***]

For clarity, the amendments in Section 12)a. through 12)d. are not effective until the Outstanding Patent Costs and Fees are received by Penn.

13) For clarity, all prosecution and enforcement rights granted to Licensee under the License Agreement can be further granted by Licensee to a Sublicensee under a Sublicense subject to the terms and conditions of the Agreement and specifically Section 2.4. Any agreement that Licensee, its Affiliates, or any Sublicensee enters into with a Third Party that provides a license or right to negotiate a license to any Patent Rights listed in Exhibit A that are jointly owned by Penn and Licensee (or any successor or assignee interest therein) shall be considered a Sublicense for the purposes of the License Agreement, in such Patent Rights.
14) Penn acknowledges and agrees that: (a) Kira Pharmaceuticals (Suzhou) Ltd., an Affiliate of Licensee, is or will be granting an exclusive license to Licensee under its interest in the Penn Patent Rights jointly owned by Penn and Kira Pharmaceuticals (Suzhou) Ltd. and (b) in conjunction with the Reverse Merger Transaction, pursuant to which Licensee will merge with and into Kira Holdco Inc. a Delaware corporation, with Kira Holdco Inc. succeeding to the rights and obligations of Licensee under applicable law, such succession and transfer of the License Agreement to Kira Holdco Inc., shall become effective upon consummation of the Reverse Merger Transaction, provided that: (i) Licensee is not in breach of the License Agreement immediately prior to the effective time of the Reverse Merger Transaction; (ii) Kira Holdco Inc. confirms in writing within [***] following consummation of the Reverse Merger Transaction that it is bound by and assumes all obligations under the License Agreement; and (iii) all amounts due and owing to Penn under the License Agreement as of the effective time of the Reverse Merger Transaction have been paid. For the avoidance of doubt, Licensee shall remain responsible for all liabilities and obligations accrued under the License Agreement prior to the effective time of the Reverse Merger Transaction.
15) Unless otherwise defined herein, capitalized terms will have the definitions given them in the License Agreement.
16) This Third Amendment, together with the License Agreement, constitute the entire agreement between the parties. All other terms and provisions of the License Agreement, except as expressly amended by this Third Amendment, remain in full force and effect.
17) This Third Amendment may be executed in two or more counterparts, each of which shall be deemed an original and together shall be deemed one and the same instrument.

[Signature page follows]

5

IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this Third Amendment to be executed by their duly authorized representatives.

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
By: */s/ *Benjamin Dibling, Ph.D.
Name: Benjamin Dibling, Ph.D.
Title: Associate Vice Provost for Research & Managing Director, Penn Center for Innovation
Date: 7/9/2026
KIRA PHARMACEUTICALS
By: /s/ Patrick Crutcher
Name: Patrick Crutcher
Title: Board Member
Date: 07/09/2026
6

Appendix I

Exhibit A

Patents and Patent Applications in Penn Patent Rights

[***]

7
Back to all agreements